IL‐6 stimulation of DNA replication is JAK1/2 mediated in cross‐talk with hyperactivated ERK1/2 signaling. (7th January 2019)

• Record Type: Journal Article
• Authors: Subotički, Tijana; Mitrović Ajtić, Olivera; Beleslin‐Čokić, Bojana B.; Bjelica, Sunčica; Djikić, Dragoslava; Diklić, Miloš; Leković, Danijela; Gotić, Mirjana; Santibanez, Juan F.; Noguchi, Constance T.; Čokić, Vladan P.
• Is Part Of: Cell biology international. Volume 43:Number 2(2019)
• Page Start: 192
• Page End: 206
• Publication Date: 2019-01-07
• Subjects: cell cycle -- ERK1/2 signaling -- inflammation -- JAK1/2 inhibition -- myeloproliferative neoplasm; Cytology -- Periodicals; Cells -- Periodicals; 571.605
• DOI: 10.1002/cbin.11084
• Languages: English
• ISSNs: 1065-6995

Abstract

Abstract: Myeloproliferative neoplasms (MPNs) are developing resistance to therapy by JAK1/2 inhibitor ruxolitinib. To explore the mechanism of ruxolitinib's limited effect, we examined the JAK1/2 mediated induction of proliferation related ERK1/2 and AKT signaling by proinflammatory interleukin‐6 (IL‐6) in MPN granulocytes and JAK2 V617F mutated human erythroleukemia (HEL) cells. We found that JAK1/2 or JAK2 inhibition prevented the IL‐6 activation of STAT3 and AKT pathways in polycythemia vera and HEL cells. Further, we showed that these inhibitors also blocked the IL‐6 activation of the AKT pathway in primary myelofibrosis (PMF). Only JAK1/2 inhibitor ruxolitinib largely activated ERK1/2 signaling in essential thrombocythemia and PMF (up to 4.6 fold), with a more prominent activation in JAK2 V617F positive granulocytes. Regarding a cell cycle, we found that IL‐6 reduction of HEL cells percentage in G2M phase was reversed by ruxolitinib (2.6 fold). Moreover, ruxolitinib potentiated apoptosis of PMF granulocytes (1.6 fold). Regarding DNA replication, we found that ruxolitinib prevented the IL‐6 augmentation of MPN granulocytes frequency in the S phase of the cell cycle (up to 2.9 fold). The inflammatory stimulation induces a cross‐talk between the proliferation linked pathways, where JAK1/2 inhibition is compensated by the activation of the ERK1/2 pathway during IL‐6 stimulation of DNA replication.